SFY0 Stock Overview
A clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Theriva Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.42 |
| 52 Week High | US$14.00 |
| 52 Week Low | US$2.42 |
| Beta | 1.38 |
| 11 Month Change | -46.22% |
| 3 Month Change | -57.36% |
| 1 Year Change | -79.14% |
| 33 Year Change | -97.64% |
| 5 Year Change | -97.48% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| SFY0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.5% |
| 1Y | -79.1% | -17.5% | 6.2% |
Return vs Industry: SFY0 underperformed the German Biotechs industry which returned -17.6% over the past year.
Return vs Market: SFY0 underperformed the German Market which returned 6.2% over the past year.
Price Volatility
| SFY0 volatility | |
|---|---|
| SFY0 Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: SFY0's share price has been volatile over the past 3 months.
Volatility Over Time: SFY0's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 22 | Steve Shallcross | therivabio.com |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
Theriva Biologics, Inc. Fundamentals Summary
| SFY0 fundamental statistics | |
|---|---|
| Market cap | €5.37m |
| Earnings (TTM) | -€20.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs SFY0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFY0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$22.27m |
| Earnings | -US$22.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -22.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.6% |
How did SFY0 perform over the long term?
See historical performance and comparison